Use of Intraaortic Balloon Counterpulsation in Patients Presenting With Cardiogenic Shock: Observations From the GUSTO-I Study fn1fn1This study was funded by grants from Bayer, New York, New York; CIBA-Corning, Medfield, Massachusetts; Genentech, South San Francisco, California; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France.

This publication has 30 references indexed in Scilit:

• Contemporary reperfusion therapy for cardiogenic shock: The GUSTO-I trial experience
  Journal of the American College of Cardiology, 1995
• Intraaortic balloon counterpulsation enhances coronary thrombolysis induced by intravenous administration of a thrombolytic agent
  Journal of the American College of Cardiology, 1994
• An analysis of the cause of early mortality after administration of thrombolytic therapy
  Coronary Artery Disease, 1993
• Marked systemic hypotension depresses coronary thrombolysis induced by intracoronary administration of recombinant tissue-type plasminogen activator
  Journal of the American College of Cardiology, 1992
• Mechanisms of early death despite thrombolytic therapy: Experience from the Thrombolysis in Myocardial Infarction Phase II (TIMI II) study
  Journal of the American College of Cardiology, 1992
• Cardiogenic Shock after Acute Myocardial Infarction
  New England Journal of Medicine, 1991
• In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin
  The Lancet, 1990
• Results of a randomized prospective trial of intraaortic balloon counterpulsation and intravenous nitroglycerin in patients with acute myocardial infarction
  Journal of the American College of Cardiology, 1985
• Randomized controlled trial of intraaortic balloon counterpulsation in early myocardial infarction with acute heart failure
  The American Journal of Cardiology, 1981
• Intra-Aortic Balloon Counterpulsation in Cardiogenic Shock
  New England Journal of Medicine, 1973